Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt

Nagaty, Ahmed; Abd El-Wahab, Ekram W.
October 2017
PLoS ONE;10/05/2017, Vol. 12 Issue 10, p1
Academic Journal
Background: More than ten million Egyptians are infected with HCV. Every one of them is going to infect about three to four persons every year. Treating those patients is a matter of national security. A dramatic improvement in hepatitis C virus (HCV) infection treatment was achieved in the last five years. A new era of direct-acting antivirals is now dawning in Egypt. Objective(s): We share in this report our clinical experience in treating chronic HCV Egyptian patients with Sofosbuvir based regimens to evaluate its safety and efficacy on real life practical ground. Methods: A total of 205 chronic HCV patients (195 naive and 15 experienced) were enrolled in the study. Patient were treated with Sofosbuvir+Ribavirin 24 weeks as standard of care. Two interferon eligible patients were treated with PEG-INF+ Sofosbuvir+Ribavirin for 12 weeks. The primary efficacy endpoint was the proportion of patients with sustained virologic response at 24 weeks after cessation of therapy. Results: The overall response rate was 97.1%. Sustained virological response rate did not differ among treatment-naive patients and patients with previous history of IFN-based therapy. Portal hypertension, prediabetes, and lack of early virologic response were predictors of non response. No clinically significant treatment-emergent adverse effects were noted. No treatment discontinuation was encountered. Conclusion: In the real-life setting, Sofosbuvir based regimens for 24 weeks has established an efficacious and well tolerated treatment in naïve and experienced patients with chronic HCV genotype 4 infection; although shorter treatment durations may be possible. However, patient follow up should extent to at least 6 months post-treatment and verifying viral load on yearly basis is warranted to track any late relapse.


Related Articles

  • Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Yoshida, Eric M.; Kwo, Paul; Agarwal, Kosh; Duvoux, Christophe; Durand, François; Peck-Radosavljevic, Markus; Lilly, Leslie; Willems, Bernard; Vargas, Hugo; Kumar, Princy; Brown Jr., Robert S.; Horsmans, Yves; De-Oertel, Shampa; Arterburn, Sarah; Dvory-Sobol, Hadas; Brainard, Diana M.; McHutchison, John G.; Terrault, Norah; Rizzetto, Mario; Müllhaupt, Beat // Annals of Hepatology: Official Journal of the Mexican Associatio;May/Jun2017, Vol. 16 Issue 3, p375 

    Introduction. Recurrence of HCV infection in patients with chronic hepatitis C virus (HCV) at the time of liver transplantation is nearly universal and reduces the likelihood of graft and patient survival. Materials and methods. We evaluated outcomes of 17 patients (16 with HCV genotype 1 and 1...

  • Sofosbuvir-Ribavirin Duo for Chronic Hepatitis C. NJEI, BASILE // Connecticut Medicine;Jun/Jul2014, Vol. 78 Issue 6, p355 

    The article discusses research on the effectiveness of sofosbuvir, a nucleotide polymerase inhibitor, in combination with ribavirin in the treatment of chronic hepatitis C virus (HCV) infections. Information on a meta-analysis of pooled sustained virological response (SVR) for HCV patients is...

  • Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines. Harada, Naoki; Hiramatsu, Naoki; Oze, Tsugiko; Yamada, Ryoko; Kurokawa, Mika; Miyazaki, Masanori; Yakushijin, Takayuki; Miyagi, Takuya; Tatsumi, Tomohide; Kiso, Shinichi; Kanto, Tatsuya; Kasahara, Akinori; Oshita, Masahide; Mita, Eiji; Hagiwara, Hideki; Inui, Yoshiaki; Katayama, Kazuhiro; Tamura, Shinji; Yoshihara, Harumasa; Imai, Yasuharu // Journal of Gastroenterology;Apr2013, Vol. 48 Issue 4, p535 

    Background: This study was conducted to evaluate Japanese treatment guidelines for patients with chronic hepatitis C virus (HCV) infection and normal alanine aminotransferase (N-ALT) levels from the viewpoint of the incidence of hepatocellular carcinoma (HCC). Methods: Four groups of patients...

  • Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Feld, Jordan J.; Maan, Raoel; Zeuzem, Stefan; Kuo, Alexander; Nelson, David R.; Di Bisceglie, Adrian M.; Manns, Michael P.; Sherman, Ken; Frazier, Lynn M.; Sterling, Richard; Mailliard, Mark; Schmidt, Monica; Akushevich, Lucy; Vainorius, Monika; Fried, Michael W. // Clinical Infectious Diseases;9/15/2016, Vol. 63 Issue 6, p776 

    Background. Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies lead to high rates of sustained virologic response (SVR). However, genotype 3 (GT3) HCV remains a challenge with lower SVR rates reported, particularly in patients with cirrhosis. This...

  • Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection. Ismail, Mona H. // Journal of Family & Community Medicine;Apr2013, Vol. 20 Issue 1, p35 

    Background and Aim: Hepatitis C virus (HCV) infection is a major health problem worldwide. Genotype-4 is the most common genotype in Saudi Arabia. The response to treatment with pegylated interferon-α combined with ribavirin in chronic HCV infection varies. This study aimed at investigating...

  • Hepatitis C Virus-Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case Report. di Biase, Lazzaro; Picillo, Marina; Eliza Freitas, Maria; Bui, Esther; Fasano, Alfonso; Freitas, Maria Eliza // Annals of Internal Medicine;3/7/2017, Vol. 166 Issue 5, p379 

    A case study of a 61 years old patient suffering with hepatitis C virus (HCV) is presented. It presents information on the impact of hepatic myelopathy complications on liver dysfunction of the patient with HCV. It also includes information on the treatment of the patient with sofosbuvir and...

  • Advances in the Care of Patients with Chronic Hepatitis C Infection in Connecticut: Epidemiology, Screening, and Treatment. McCARTY, THOMAS R.; LOMBARD, ANDREA; K. LIM, JOSEPH // Connecticut Medicine;Apr2018, Vol. 82 Issue 4, p197 

    Despite the variable course of hepatitis C virus (HCV) infection, HCV is estimated to account for approximately 40% of all chronic liver disease in the US. This significant burden of HCV infection within the US parallels the current challenges within the state of Connecticut. While barriers to...

  • Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience. Hassan, Amro M; Osman, Heba A; Mahmoud, Hasan S; Hassan, Mohammed H; Hashim, Abdel-Kader A; Ameen, Hesham H // Infection & Drug Resistance;Jun2018, Vol. 11, p895 

    Background and aims: Hepatitis C virus (HCV) infection is associated with extrahepatic manifestations such as cryoglobulinemia and accounts for up to 90% of all cases of mixed cryoglobulinemia (MC). The present study aimed to evaluate the effect of sofosbuvir–­daclatasvir therapy on...

  • Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus- infected patients. Mustafa, Mubin; Hussain, Sofia; Qureshi, Saleem; Malik, Salman Akbar; Kazmi, Ali Raza; Naeem, Muhammad // BMC Gastroenterology;2012, Vol. 12 Issue 1, p1 

    Background: Hepatitis C virus (HCV) infection is one of the leading causes of chronic liver disease (CLD). About 80% of those exposed to the virus develop a chronic infection. Hyperhomocysteinemia, which is an independent risk factor for atherosclerotic vascular disease and thromboembolism, may...

  • Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. Kobayashi, Mariko; Suzuki, Fumitaka; Akuta, Norio; Sezaki, Hitomi; Suzuki, Yoshiyuki; Hosaka, Tetsuya; Kawamura, Yusuke; Kobayashi, Masahiro; Saitoh, Satoshi; Arase, Yasuji; Ikeda, Kenji; Chayama, Kazuaki; Miyakawa, Yuzo; Kumada, Hiromitsu // Journal of Gastroenterology;May2012, Vol. 47 Issue 5, p596 

    Background: Two nucleotide polymorphisms of the interleukin-28B ( IL28B) gene, at rs8099917 and rs12979860, influence the response to interferon (IFN)-based therapies in patients infected with hepatitis C virus (HCV) of genotype 1. We aimed to investigate whether these polymorphisms showed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics